ArticleJACC. CardioOncology2026
Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site.
Article in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02832245 (Computerized Registry of Patients With Venous Thromboembolism), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Who cites it
1 citing paper in PubMed.
- Upper-Extremity Deep Vein Thrombosis in Cancer: Beyond a Catheter-Related Complication.JACC. CardioOncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper extremity deep vein thrombosis (UEDVT) is common in patients with cancer. Data on recurrence and bleeding after cancer-associated UEDVT are limited.
objectivesThe objectives were to identify factors associated with venous thromboembolism (VTE) recurrence and bleeding in patients with cancer and UEDVT, overall and by cancer site, during and after anticoagulation.
methodsWe analyzed patients from the Registro Informatizado de Pacientes con Enfermedad TromboEmbólica (RIETE), an international, prospective, observational registry of objectively confirmed VTE. We estimated cumulative incidence functions at 6, 12, 18, and 24 months and used proportional subdistribution hazard models to assess associations. Analyses were performed during and after discontinuation, using a landmark at the day of discontinuation if anticoagulation was stopped within 180 days or at day 180 if anticoagulation continued more than 180 days.
resultsOf 5,195 patients with UEDVT, 2,210 had cancer. At 24 months, the cumulative incidence of recurrent VTE was 3.9% (95% CI: 3.1-4.9) in patients with cancer vs 2.5% (95% CI: 1.8-3.5) in those without cancer, and the cumulative incidence of bleeding was 6.8% (95% CI: 5.7-8.1) vs 4.3% (95% CI: 3.4-5.3), respectively (both P < 0.001). Among patients with cancer, 24-month recurrence varied by cancer site: lung, 6.4% (95% CI: 4.0-9.5); gastrointestinal, 4.0% (95% CI: 2.6-6.0); genitourinary, 3.6% (95% CI: 1.6-6.8); breast, 2.5% (95% CI: 1.2-4.5); and hematologic, 1.4% (95% CI: 0.5-3.4). During anticoagulation, lung cancer (subdistribution hazard ratio [sHR]: 10.1; 95% CI: 1.31-78.06) and younger age (per-year sHR: 0.97; 95% CI: 0.95-0.99) were associated with recurrence, whereas genitourinary cancer (sHR: 4.95; 95% CI: 1.16-21.17) and transient risk factors (sHR: 1.75; 95% CI: 1.16-2.64) were associated with bleeding. After anticoagulation discontinuation, 91 to 180 days (sHR: 0.49; 95% CI: 0.24-1.00) and more than 180 days (sHR: 0.35; 95% CI: 0.17-0.71) of anticoagulation were associated with lower recurrence vs 30 days or less.
conclusionsCancer-associated UEDVT carries higher risks of recurrence and bleeding than noncancer UEDVT. Lung cancer showed the greatest recurrence during treatment. Anticoagulation beyond 90 days was associated with a lower post-treatment recurrence. (Computerized Registry of Patients With Venous Thromboembolism [RIETE]; NCT02832245).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.